AACR 2023: Assessing replication stress as an actionable therapeutic opportunity in chordoma

In this poster, we detail what we've learned about a recent hypothesis called replication stress in chordoma. Additionally, we provide rationale for exploiting it therapeutically with gemcitabine, a widely-used, low-cost cancer drug, and a class of drugs called ATR inhibitors, which are currently in clinical development. More about these potential new therapeutic options can be found here.